Spyre Therapeutics Inc (SYRE) Stock Analysis
Verdict: HOLD
A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics.
Investment score: 44/100
Analysis as of
Is Spyre Therapeutics Inc stock worth reviewing? AI model thesis
The model score of 44/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Spyre Therapeutics Inc opportunities and risks
What speaks for SYRE
- Differentiated anti-TL1A and anti-a4ß7 portfolio targeting massive IBD market
What speaks against SYRE
- Binary clinical trial failure across preclinical candidates SPY001 and SPY002
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SYRE | n/a | 83.8x | n/a | 0.0% | -197.7% | -2.8% |
| TGTX | 18.3x | 10.7x | 65.5x | 82.4% | 55.2% | -0.0% |
| TWST | n/a | 17.9x | n/a | 52.0% | -31.7% | -1.2% |
| IMVT | n/a | 1134.8x | n/a | 97.1% | -7585.9% | -5.1% |
| RYTM | n/a | 29.5x | n/a | 89.0% | -85.6% | -2.1% |
| CAI | 67.0x | 7.1x | 39.4x | 69.7% | 10.6% | 2.1% |
| Peer median | n/a | 17.9x | n/a | 82.4% | -31.7% | -1.2% |
Frequently asked questions about Spyre Therapeutics Inc (SYRE)
Is SYRE stock a good investment?
The cached TradeMates AI model rates Spyre Therapeutics Inc as HOLD with an investment score of 44/100. The model score of 44/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is SYRE stock a buy?
The TradeMates model verdict for SYRE is HOLD with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.